Health

Pfizer and Sanofi helped the precision medicine developer close a series B round which will be used to advance and expand its pipeline of respiratory disease drug candidates.

Sumitomo Mitsui’s DS Asset Management subsidiary backed the neurological and metabolic disorder drug developer in a round that will support clinical trials.

Eli Lilly, WuXi AppTec and Schrodinger were among the investors in the cardiovascular, pulmonary and metabolic disorder drug developer's latest round.

Digital health drives healthcare investments to record heights

Battery swapping service Sun Mobility closed $50m in funding from Vitol while Sinopharm-backed drug developer Sinotau raised the same amount in a series D-plus round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Amgen, Merck & Co, Pfizer, Intermountain and McKesson were among the investors to jointly acquire a majority of the clinical trials software producer's shares.

The WuXi AppTec-backed hepatitis specialist replenished its coffers in a series A-plus round led by Hillhouse Capital fund GL Capital.

MS&AD Ventures and Mouro Capital helped privacy management technology provider Skyflow secure $45m while neurotherapeutics developer Cecerin revealed $40m from investors including Nestlé.

AstraZeneca, Eli Lilly and Sinopharm all achieved exits as the cancer therapy developer listed on the Hong Kong Stock Exchange at a reported valuation of nearly $1.1bn.

The cancer immunotherapy developer, which counts Novo and Lundbeck as investors, filed to raise up to $100m in its initial public offering.